Immunotherapy for Low-Grade Non-Hodgkin Secondary Lymphoma of the Orbit

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text

Life Sciences, Immunology, Pathology +14

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer et al. · PubMed · 1998 · 898 citations

Life Sciences, Immunology, Oncology +15

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

DG Maloney, A.J. Grillo-López, David Bodkin et al. · Journal of Clinical Oncology · 1997 · 638 citations

Pharmacy, Hematology, Pharmacokinetics +17